Insider Selling: LeMaitre Vascular (NASDAQ:LMAT) Insider Sells 1,044 Shares of Stock

LeMaitre Vascular, Inc. (NASDAQ:LMAT) insider Trent Kamke sold 1,044 shares of LeMaitre Vascular stock in a transaction that occurred on Friday, February 27th. The stock was sold at an average price of $110.29, for a total transaction of $115,142.76. Following the completion of the transaction, the insider directly owned 6,677 shares in the company, valued at approximately $736,406.33. This trade represents a 13.52% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

LeMaitre Vascular Trading Down 0.7%

Shares of NASDAQ:LMAT traded down $0.79 during mid-day trading on Monday, hitting $107.39. The stock had a trading volume of 330,860 shares, compared to its average volume of 213,077. The company’s 50 day moving average is $87.47 and its 200-day moving average is $88.40. LeMaitre Vascular, Inc. has a 12-month low of $71.42 and a 12-month high of $115.33. The company has a debt-to-equity ratio of 0.43, a quick ratio of 10.95 and a current ratio of 12.89. The company has a market cap of $2.45 billion, a PE ratio of 42.78, a P/E/G ratio of 2.01 and a beta of 0.66.

LeMaitre Vascular (NASDAQ:LMAT) last posted its quarterly earnings data on Wednesday, February 25th. The medical instruments supplier reported $0.68 earnings per share for the quarter, topping the consensus estimate of $0.67 by $0.01. The firm had revenue of $64.45 million for the quarter, compared to analysts’ expectations of $62.98 million. LeMaitre Vascular had a net margin of 23.13% and a return on equity of 14.72%. The company’s quarterly revenue was up 15.7% compared to the same quarter last year. During the same period in the previous year, the company posted $0.49 EPS. LeMaitre Vascular has set its FY 2026 guidance at 2.810-3.010 EPS and its Q1 2026 guidance at 0.640-0.690 EPS. On average, sell-side analysts predict that LeMaitre Vascular, Inc. will post 1.94 EPS for the current year.

LeMaitre Vascular Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 26th. Shareholders of record on Thursday, March 12th will be paid a dividend of $0.25 per share. This is a boost from LeMaitre Vascular’s previous quarterly dividend of $0.20. The ex-dividend date of this dividend is Thursday, March 12th. This represents a $1.00 annualized dividend and a yield of 0.9%. LeMaitre Vascular’s dividend payout ratio (DPR) is presently 31.87%.

Institutional Trading of LeMaitre Vascular

Large investors have recently modified their holdings of the company. M&T Bank Corp increased its stake in LeMaitre Vascular by 2,240.5% during the fourth quarter. M&T Bank Corp now owns 398,069 shares of the medical instruments supplier’s stock valued at $32,283,000 after acquiring an additional 381,061 shares during the period. Goldman Sachs Group Inc. boosted its stake in LeMaitre Vascular by 144.4% during the fourth quarter. Goldman Sachs Group Inc. now owns 391,254 shares of the medical instruments supplier’s stock worth $31,731,000 after buying an additional 231,157 shares in the last quarter. First Trust Advisors LP increased its holdings in LeMaitre Vascular by 35.4% in the 3rd quarter. First Trust Advisors LP now owns 828,947 shares of the medical instruments supplier’s stock valued at $72,541,000 after buying an additional 216,919 shares during the period. Millennium Management LLC raised its stake in shares of LeMaitre Vascular by 119.8% in the 1st quarter. Millennium Management LLC now owns 211,222 shares of the medical instruments supplier’s stock valued at $17,722,000 after buying an additional 115,141 shares in the last quarter. Finally, Geode Capital Management LLC lifted its holdings in shares of LeMaitre Vascular by 20.1% during the 4th quarter. Geode Capital Management LLC now owns 633,089 shares of the medical instruments supplier’s stock worth $51,351,000 after acquiring an additional 105,921 shares during the period. 84.64% of the stock is owned by institutional investors.

Analyst Ratings Changes

LMAT has been the subject of a number of research analyst reports. Weiss Ratings lowered shares of LeMaitre Vascular from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Tuesday, February 24th. Roth Mkm reiterated a “buy” rating and issued a $117.00 target price (up from $108.00) on shares of LeMaitre Vascular in a research report on Thursday. Citizens Jmp lifted their target price on shares of LeMaitre Vascular from $113.00 to $118.00 and gave the company a “market outperform” rating in a research note on Thursday. Zacks Research downgraded shares of LeMaitre Vascular from a “strong-buy” rating to a “hold” rating in a research note on Thursday, January 1st. Finally, Wells Fargo & Company lifted their price objective on LeMaitre Vascular from $87.00 to $94.00 and gave the company an “equal weight” rating in a research report on Thursday. Three equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $105.80.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.